Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Cancer
BrightGene’s Generic Halaven Approved for Marketing in China
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...
ClinChoice Acquires Cromsource to Expand Global CRO Footprint
Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...
Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy
Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...
Merck Reports 12.9% Sales Growth in 2022 Annual Report
German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...
Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib
Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...
HutchMed Reports 2022 Financial Results with Revenue Growth
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...
JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Sanofi’s Sarclisa Approved for Import in Shenzhen via Greater Bay Area Scheme
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...